Prevalence of metabolic syndrome in a predominantly Cuban, psychiatrically ill, and homeless population

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 13, Issue 3, 2011, Pages

  Rivas Vazquez, Rafael A ^a   Bello, Iruma ^a   Sarria, Manual ^a   Fernandez, Noel D ^a   Rey, Gustavo J ^b  

^a Citrus Health Network   (United States)

^b MIAMI CHILDREN'S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; CUBAN; CUBAN AMERICAN; ETHNIC GROUP; FEMALE; HISPANIC; HOMELESSNESS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; MOOD DISORDER; OUTPATIENT; PREVALENCE; RETROSPECTIVE STUDY; RISK FACTOR; SCHIZOPHRENIA; WAIST CIRCUMFERENCE;

EID: 79960251412     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.10m01002     Document Type: Article

References (16)

1. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA. 2002;287(3):356-359. doi:10.1001/jama.287.3.356
2. Ervin RB. Prevalence of Metabolic Syndrome Among Adults 20 Years of Age And Over, By Sex, Age, Race and Ethnicity, and Body Mass Index: United States, 2003-2006. National Health Statistics Reports; No. 13. Hyattsville, MD: National Center for Health Statistics; 2009.
3. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25): 3143-3421.
4. Saha S, Chant D, McGrath J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch Gen Psychiatry. 2007;64(10):1123-1131. doi:10.1001/archpsyc.64.10.1123
5. Roshanaei-Moghaddam B, Katon W. Premature mortality from general medical illnesses among persons with bipolar disorder: a review. Psychiatr Serv. 2009;60(2):147-156. doi:10.1176/appi.ps.60.2.147
6. Heiskanen T, Niskanen L, Lyytikäinen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry. 2003;64(5):575-579. doi:10.4088/JCP.v64n0513
7. McEvoy JP, Meyer JM, Goff DC, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80(1):19-32. doi:10.1016/j.schres.2005.07.014
8. Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord. 2005;7(5):424-430. doi:10.1111/j.1399-5618.2005.00234.x
9. O'Connell JJ. Premature mortality in homeless populations: a review of the literature. Nashville, TN: National Health Care for the Homeless Council; 2005. http://www.nhchc.org/PrematureMortalityFinal.pdf. Accessed February 25, 2011.
10. Hwang SW. Mortality among men using homeless shelters in Toronto, Ontario. JAMA. 2000;283(16):2152-2157. doi:10.1001/jama.283.16.2152
11. Szerlip MI, Szerlip HM. Identification of cardiovascular risk factors in homeless adults. Am J Med Sci. 2002;324(5):243-246. doi:10.1097/00000441-200211000-00002
12. Lee TC, Hanlon JG, Ben-David J, et al. Risk factors for cardiovascular disease in homeless adults. Circulation. 2005;111(20):2629-2635. doi:10.1161/CIRCULATIONAHA.104.510826
13. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27(2):596-601. doi:10.2337/diacare.27.2.596
14. Grundy SM. Hypertriglyceridemia, insulin resistance, and the metabolic syndrome. Am J Cardiol. 1999;83(9B):25F-29F. doi:10.1016/S0002-9149(99)00211-8
15. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res. 2004;70(1):1-17. doi:10.1016/j.schres.2004.01.014
16. Meyer JM, Rosenblatt LC, Kim E, et al. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. J Clin Psychiatry. 2009;70(3):318-325. doi:10.4088/JCP.08m04267